Nuvectis Pharma, Inc.(NVCT)

Biotechnology · Fort Lee, NJ

$20.09-1.30 (-6.09%)

Delayed quote: Oct 6, 2026, 2:24 PM EDT

EBITDA Yield: N/A

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T18:27:46.048Z.

Stored calculation inputs

Calculation as of: 2026-10-06T18:27:46.048Z.

Quote observation: 2026-10-06T18:24:51.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -28,868,000
Quote market capitalization: 533,024,001
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 22,160,000

FMP input reference: b447d722f006e82d19b5d98ef6acffd249f934693947ae19b5e437b2b2585766

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

NVCT EBITDA Yield Metrics

EBITDA YIELD

N/A

NVCT Competitors' EBITDA Yield

NVCT

Nuvectis Pharma, Inc.

Current

Market Cap

$533.02M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PHAT

Phathom Pharmaceuticals, Inc.

vs NVCT

Market Cap

$533.82M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DCTH

Delcath Systems, Inc.

vs NVCT

Market Cap

$536.29M

EBITDA Yield

N/A

TTM Avg

1.23%

3Y Avg

1.23%

5Y Avg

1.23%

PROK

ProKidney Corp.

vs NVCT

Market Cap

$536.32M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ACRS

Aclaris Therapeutics, Inc.

vs NVCT

Market Cap

$521.64M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

IMMX

Immix Biopharma, Inc.

vs NVCT

Market Cap

$525.52M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

STTK

Shattuck Labs, Inc.

vs NVCT

Market Cap

$541.32M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

BLSM

BlossomHill Therapeutics, Inc.

vs NVCT

Market Cap

$524.77M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALT

Altimmune, Inc.

vs NVCT

Market Cap

$522.16M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MNPR

Monopar Therapeutics Inc.

vs NVCT

Market Cap

$547.38M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Nuvectis Pharma, Inc. (NVCT)	$533.02M	N/A	N/A	N/A	N/A
Phathom Pharmaceuticals, Inc. (PHAT)vs ›	$533.82M	N/A	N/A	N/A	N/A
Delcath Systems, Inc. (DCTH)vs ›	$536.29M	N/A	1.23%	1.23%	1.23%
ProKidney Corp. (PROK)vs ›	$536.32M	N/A	N/A	N/A	N/A
Aclaris Therapeutics, Inc. (ACRS)vs ›	$521.64M	N/A	N/A	N/A	N/A
Immix Biopharma, Inc. (IMMX)vs ›	$525.52M	N/A	N/A	N/A	N/A
Shattuck Labs, Inc. (STTK)vs ›	$541.32M	N/A	N/A	N/A	N/A
BlossomHill Therapeutics, Inc. (BLSM)vs ›	$524.77M	N/A	N/A	N/A	N/A
Altimmune, Inc. (ALT)vs ›	$522.16M	N/A	N/A	N/A	N/A
Monopar Therapeutics Inc. (MNPR)vs ›	$547.38M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

NVCT EBITDA Yield Metrics

NVCT Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics